ranolazine has been researched along with arginine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barsness, GW; Yang, EH | 1 |
| Coppola, JT; Deshmukh, SH; Hermance, EV; Infantino, MN; Mindrescu, C; Patel, SR; Pinassi, E; Staniloae, CS | 1 |
2 review(s) available for ranolazine and arginine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Evolving treatment strategies for chronic refractory angina.
Topics: Acetanilides; Angina Pectoris; Arginine; Benzazepines; Cardiovascular Agents; Chronic Disease; Combined Modality Therapy; Counterpulsation; Electric Stimulation Therapy; Humans; Ivabradine; Myocardial Revascularization; Piperazines; Randomized Controlled Trials as Topic; Ranolazine; Spinal Cord | 2006 |
1 trial(s) available for ranolazine and arginine
| Article | Year |
|---|---|
Ranolazine improves endothelial function in patients with stable coronary artery disease.
Topics: Acetanilides; Aged; Arginine; Biomarkers; C-Reactive Protein; Cardiovascular Agents; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hyperemia; Inflammation Mediators; Male; Manometry; Middle Aged; Piperazines; Ranolazine; Time Factors; Treatment Outcome; Vasodilation | 2009 |